Clinical Trials Logo

NSCLC clinical trials

View clinical trials related to NSCLC.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06247280 Active, not recruiting - NSCLC Clinical Trials

Korean Registry of Non-Small Cell Lung Cancer Patients With EGFR Mutation

Start date: June 24, 2022
Phase:
Study type: Observational [Patient Registry]

Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR mutation to collect and analyze the patient's clinical features, diagnosis, and treatment results.

NCT ID: NCT06107686 Active, not recruiting - Breast Cancer Clinical Trials

A Study of YL202 in Selected Patients With Advanced Solid Tumors

Start date: December 15, 2023
Phase: Phase 2
Study type: Interventional

This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.

NCT ID: NCT05840510 Active, not recruiting - Metastatic Cancer Clinical Trials

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

Start date: August 7, 2023
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.

NCT ID: NCT05583188 Active, not recruiting - NSCLC Clinical Trials

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

VIGOR
Start date: February 1, 2023
Phase: Phase 4
Study type: Interventional

A prospective, single-arm, non-randomized, multi-center, open-label study following patients with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields (PEF) ablation who may be candidates for standard of care neoadjuvant use of checkpoint inhibitor (nivolumab) treatment plus platinum doublet chemotherapy.

NCT ID: NCT05383898 Active, not recruiting - NSCLC Clinical Trials

Study to Evaluate D-1553 in Subjects With Lung Cancer

Start date: March 16, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2, open label study of D-1553 single agent treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic NSCLC with KRasG12C mutation

NCT ID: NCT05273047 Active, not recruiting - Nsclc Clinical Trials

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

LungKG12Ci
Start date: March 1, 2022
Phase:
Study type: Observational

The purpose of the IFCT2102 Lung KG12Ci study is to closely monitor cohort ATU applications in order to collect retrospectively, as soon as possible after inclusion and under real-life conditions, the efficacy data on sotorasib (AMG 510) as well as the demographic and molecular characteristics of patients.

NCT ID: NCT05146219 Active, not recruiting - NSCLC Clinical Trials

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Start date: April 2, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of TY-9591 tablets in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with brain or leptomeningeal metastases.

NCT ID: NCT05059522 Active, not recruiting - Ovarian Cancer Clinical Trials

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Start date: September 29, 2021
Phase: Phase 3
Study type: Interventional

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

NCT ID: NCT05058560 Active, not recruiting - NSCLC Clinical Trials

Tislelizumab in Addition to BACE in Patients With NSCLC

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm phase II trial to determine the efficacy and safety of Tislelizumab in addition to bronchial arterial chemoembolization in stage III-Ⅳ NSCLC patients who failed, refused or ineligible to receive standard treatments.

NCT ID: NCT05009329 Active, not recruiting - Solid Tumor Clinical Trials

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Start date: July 26, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

To assess safety, tolerability, PK, efficacy and determine recommended phase 2 dose (RP2D) of JAB-21822 (glecirasib) administered in adult participants with KRAS p.G12C-mutant advanced solid tumors.